1.Study of honokiol's antagonising effect on calmodulin
Chinese Pharmacological Bulletin 1987;0(01):-
Using calmodulin dependent cyclic neucleotide phosphodiesterase and dansyl-labeled calmodulin,honokiol's action on calmodulin is studied. It is found that honokiol inhibits the activity of cyclic neucleotide phosphodiesterase induced by stimulus of calmodulin. With the increasing of calmodulin concentration, the IC50 value was increased. In the presence of Ca2+, honokiol reduces the fluorescence intensity of dansyl-calmodulin, and makes the spectrumpeaked red. The results indicate that honokiol can combine with calmodulin in the presence of Ca2+ and antagonise the effect caused by calmodulin's stimulation upon the phosphodiesterase. In addition , honokiol may exert its effect on the basal activity of calmodulin dependent cyclic neucleotide phosphodiesterase.
2.Three-step chemotherapy after primary debulking surgery in 15 patients with stage Ⅲc or Ⅳovarian cancer
Shumo CAI ; Jie TANG ; Xiao HUANG ; Xiaowei HUANG ; Suping LIU
China Oncology 2013;(12):980-983
Background and purpose:More than 70 percent of ovarian cancer patients were diagnosed in the advanced stage. Currently the 5-year disease free survival (DFS) of stageⅢC-Ⅳovarian cancer patients wsa about 10 percent after first line chemotherapy. This study aimed to improve the 5-year DFS by three-step chemotherapy according to the mechanisms of ovarian cancer biological characteristics, cytodynamics and pharmacology. Methods:In arm A, the patients received three-step chemotherapy after primary debulking surgery, step one with paclitaxel plus carboplatin (TC regimen), every 3 weeks for 6 to 8 cycles;step two with etoposide plus cyclophosphamide, every 4 weeks for 6 cycles;step three wit carboplatin plus cyclophosphamide every eight weeks for six cycles. In control arm B, we retrospectively analysed 51 cases withⅢC-Ⅳstage ovarian cancer, who had completely response after standard chemotherapy with six to eight cycles of TC after primary surgery during 2007. We compared the 5-year DFS between the two arms. Results:The 5-year DFS of 15 cases in arm A was 80%(12/15), which was signiifcantly higher than that of arm B (5.9%, 3/51, P<0.01). Conclusion: The three-step chemotherapy after optimal debulking surgery in stageⅢC-Ⅳ can improve the 5-year DFS. This regimen is high efficacy, mild side-effect witn low cost, which deserves further exploration.
3.Combined treatment and prognostic analysis of advanced epithelial ovarian carcinoma
Xiao HUANG ; Shumo CAI ; Jianxuan FAN ; Ziting LI
Chinese Journal of Obstetrics and Gynecology 2001;0(05):-
Objective To evaluate the effects of combined treatment for advanced epithelial ovarian carcinoma and to analyze its prognostic factors Methods Fifty three patients treated with a three step combined therapeutic regimen were defined as research arm The procedures of the three step combined treatment were as follows: induction of tumor remission, sequential chemotherapy and adjuvant immunotherapy Three hundred and eighteen patients with advanced epithelial ovarian carcinoma treated with cytoreductive surgery and systemic chemotherapy were retrospectively classified into control arm Results The rates of complete response and partial response in the research arm were significantly differed from those in the control arm (90 6%, 5 7% Vs 70 1%, 5 3%, P
4.Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis
Xiao HUANG ; Shumo CAI ; Jie TANG ; Ziting LI ; Rongyu ZANG
Chinese Journal of Obstetrics and Gynecology 2000;0(09):-
Objective To investigate individualized and multi-phase management of recurrent epithelial ovarian carcinoma in order to improve survival of the patients. Methods From 1998 to 2002, 70 patients with recurrent epithelial ovarian carcinoma were enrolled in the present study. The treatments were divided into: (1) Induction of tumor remission:platinum sensitive patients were treated with paclitaxol + cisplatin (TP) or carboplatin + cyclophosphamide(CP)regimen; platinum resistant patients used Taxol + mitomycin(TM)or etoposide+ mitomycin(VM)regimen. Resection of tumors was done in an attempt to reduce the residual tumor with a diameter less than 1cm. Local radiotherapy was performed for those with residual tumor and who achieved clinical response after chemotherapy or surgery. (2) Consolidation therapy: chemotherapy with lower doses was administrated after disease remission. Interferon was used as immunotherapy during chemotherapy and radiotherapy. Survial analysis was done. Results (1) The 1, 2, 3, 4, 5-year survival rates were 67%, 51%, 45%, 38%, 32% . Median survival was 38.57 months. (3)The 1,2,3-year progression-free survival rates of the research arm were 41%, 37%, 24%. Median progression-free survival was 12.00 months. (4) Multivariate analysis revealed that platinum-free interval (P
5.The role of CK7 monoclonal antibodies in indentification of primary and metastatic malignant ascites due to ovarian carcinoma
Xiao HUANG ; Jianxuan FAN ; Shumo CAI ; Al ET
China Oncology 2000;0(06):-
Purpose:In order to deterimine the role of CK7 and other monoclonal antibodies in identification of primary and metastatic malignant ascites due to ovarian carcinoma.Methods:We used immunocytochemical ABC assay to detect the experssions of CK7、MG7、CEA、AB、CK、CK8、EMA、HBME、LCA、VIM monoclonal antibodies in 43 ascitic samples and 22 specimens. Chi square was used for statistic assay with SPSS 8.0 software. Results:One way ANOV assay showed that: (1) Cytokeratin 7 monoclonal antibody can be a very useful mark of primary ovarian carcinoma. (2) MG7 expression in peritoneal cells was significantly different in primary ovarian cancer and metastatic ovarian carcinoma of gastric origin. (3) CEA can be helpful in suggesting the origin of intestine carcinoma or not. (4) Immunohistochemical study of the peritoneal fluids showed results, similar to those in specimens. Conclusions: Immunocytochemical assay in the peritoneal fluids is a helpful diagnostic modality in differentiating between primary and metastatic ascites due to ovarian carcinoma.
6.Recurrent epithelial ovarian carcinoma: combined treatment and prognostic factors
Xiao HUANG ; Shumo CAI ; Jianxuan FAN ; Al ET
China Oncology 2001;0(05):-
Purpose:In order to improve the survival rate of recurrent ovarian carcinoma, influencing factors and the effects of combined therapy of recurrent epithelial ovarian carcinoma were investigated. Methods:From January 1998 to December 2000,60 patients with recurrent epithelial ovarian carcinoma were enrolled in the present study as research arm. The procedures of the combined treatment were as follows: After second cytoreductive surgery, platinum sensitive patients were treated with TP regimen (taxol+DDP) or CC regimen (CBP+CTX) and platinum resistant patients used TM regimen(taxol+MMC) or VM regimen(VP 16+MMC). Chemotherapy with 2/3 doses was continued after disease remission. Pelvic radiotherapy was performed for those with pelvic residual disease. IFN and/or IL 2 were administrated during chemotherapy and radiotherapy. 167 patients with recurrent epithelial ovarian carcinoma from January 1986 to December 1997, were retrospectively classified as control arm in this study. The patients were mainly treated with combined chemotherapy (CAP regimen) and traditional Chinese medicine applied as adjuvant therapy. Results:The rates of CR and PR in the research arm differed significantly from that in the control arm (43.33%, 45.00% vs. 2.99%, 7.78% P = 0.000). The 1 , 2 and 3 year survival rates of the research arm and control arm were 89.38%, 79.69%, 71.25% vs. 64.58%, 40.39%, 31.20% respectively ( P